Experimental Treatments for Epidermolysis Bullosa
FCX-007
FCX-007 is being developed to treat recessive dystrophic epidermolysis bullosa. It is a cell-based therapy that genetically modifies a patient’s own skin cells to produce healthy copies of type 7 collagen. It is currently being tested in an ongoing Phase 1/2 trial.